Table 1 Functional drug screening identified 39 candidate drug hits that interfered with the CAF2-inhibition of MCF7 ER-α activity at least one concentration included, without boosting MCF7 cell number or showing toxicity to the CAF2 cells.

1

Chloroquine

Anti-malaria agent; chemo/radio-sensitizer

Chemotherapy

2

Daunorubicine

Topoisomerase II inhibitor

3

Etoposide

Topoisomerase II inhibitor

4

Teniposide

Topoisomerase II inhibitor

5

Aldoxorubicin

Topoisomerase II inhibitor

6

BMS863233

Cdc7 inhibitor

Kinase inhibitor

7

Abemaciclib

CDK4/6 inhibitor

8

Palbociclib

CDK4/6 inhibitor

9

PF-670462

CK1delta/CK1epsilon inhibitor

10

DEL-22379

ERK dimerization inhibitor

11

Ulixertinib

ERK inhibitor

12

AMG-925

FLT3/CDK4 inhibitor

13

Pacritinib

JAK2/FLT3 inhibitor

14

Ruxolitinib

JAK1/2 inhibitor

15

Peficitinib

JAK3 inhibitor

16

UNC2881

MER inhibitor

17

Foretinib

MET/VEGFR2 inhibitor

18

Altiratinib

MET/Tie2 inhibitor

19

LY-2584702

P70S6K inhibitor

20

PF-00477736

P70S6K inhibitor

21

LY3009120

pan-RAF inhibitor

22

GDC-0084

PI3K/mTOR inhibitor

23

Enzastaurin

PKCbeta inhibitor

24

Ripasudil

ROCK inhibitor

25

Hydroxyfasudil

ROCK/PKA/PKG/PRK inhibitor

26

GSK269962

ROCK1/2 inhibitor

27

TEW-7197

TGF-β type I receptor ALK4/5 inhibitor

28

OTS-964

TOPK inhibitor

29

Brivanib

VEGFR inhibitor

30

UNC0642

G9a/GLP inhibitor

Differentiating and/or

epigenetic modifier

31

Valproic acid

HDAC inhibitor

32

Vidofludimus

DHODH inhibitor

33

Celecoxib

COX-2 inhibitor

NSAID

34

Glasdegib

Smo inhibitor

Hedgehog inhibitor

35

Digoxin

Cardiac glycoside

Other

36

MK-0752

Gamma-secretase/Notch1 inhibitor

37

E7820

Integrin-α2 expression inhibitor

38

NVP-LGK974

PORCN inhibitor

39

Varespladib

Secretory phospholipase A2 inhibitor